Antaike Medical Secures Tens of Millions in New Funding to Advance Minimally Invasive Atrial Fibrillation Devices

YiOu Healthcare, May 22 — Artechmed, a company specializing in minimally invasive interventional devices for atrial fibrillation (AF), recently announced the completion of a new round of financing amounting to tens of millions of yuan. The lead investor was Anlong Fund, with participation from Tengyun Capital, existing shareholder Dingxin Capital, and Sinopharm Capital. Established in November 2017, Artechmed is based in Shanghai Zhangjiang Science City and focuses on the research, development, and manufacturing of next-generation minimally invasive interventional medical devices and equipment for AF treatment. The company previously secured tens of millions of yuan in Series A financing on December 11, 2018. Its flagship product, a minimally invasive cryoablation system for AF, has entered clinical trials. Furthermore, Artechmed plans to expand its pipeline of innovative AF treatment products, pursue CE and FDA certifications, and enter international markets.